Release Notes:
Data Element
Version 2016B1
| Data Element Name: | ACEI Prescribed for LVSD in the Outpatient Setting |
|---|
| Collected For: | ACHFOP-02, |
|---|
| Definition: | Documentation that an angiotensin converting enzyme inhibitor (ACEI) was prescribed for LVSD in the outpatient setting. ACEIs widen or dilate blood vessels, lowering blood pressure and making it easier for the heart to pump blood. They also inhibit the adverse effects of neurohormonal activation on the heart. These effects help reduce the risk of adverse outcomes such as death or hospitalization. |
|---|
| Suggested Data Collection Question: | Was an angiotensin converting enzyme inhibitor (ACEI) prescribed for LVSD in the outpatient setting? |
|---|
| Format: | | Length: | 1 |
|---|
| Type: | Alphanumeric |
|---|
| Occurs: | 1 |
|---|
|
|---|
| Allowable Values: |
- Y (Yes) ACEI was prescribed for LVSD in the outpatient setting, or the patient is currently on an ACEI.
- N (No) ACEI was not prescribed for LVSD in the outpatient setting, or unable to determine from medical record documentation.
|
|---|
| Notes for Abstraction: |
- All medications prescribed in the outpatient setting should be reviewed and taken into account by the abstractor.
- If the patient is currently on an ACEI, select Yes.
|
|---|
| Suggested Data Sources: |
- Discharge summary
- Discharge instruction sheet
- Outpatient medical record
|
|---|
| Additional Notes: |
|
|---|
| Guidelines for Abstraction: |
|---|
| Inclusion | Exclusion | |
Refer to Appendic C, Table 1.2 for a comphrehensive list of ACEIs.
|
None. |
|
ACEI Prescribed for LVSD in the Outpatient Setting
Specifications Manual for Joint Commission National Quality Measures (v2016B1)
Discharges 01-01-17 (1Q17) through 06-30-17 (2Q17)
^
Warning: your browser isn't supported. Please install a modern one, like Firefox, Opera, Safari, Chrome or the latest Internet Explorer.
Thank you!